A study conducted by Persistence Market Research (PMR) shows that the global market for combination antibody therapy is set to ride on a value CAGR of over 14% during the period of assessment to reach US$ 144,734.5 Million by 2024 end.

1. Global Market Study on Combination Antibody
Therapy: Antibody/Antibody Combination
Segment Expected to Dominate the Global Market
Through 2024

2. Combination Antibody Therapy Market 2024
PersistenceMarketResearch
Report Media Releases
Combination Antibody Market in APAC Region Set to Witness
Robust Growth through 2024
Higher success ratio in treating and preventing cancer cells using combination antibody therapy
is fuelling the demand for combination antibody drugs in the market. A study conducted by
Persistence Market Research (PMR) shows that the global market for combination antibody
therapy is set to ride on a value CAGR of over 14% during the period of assessment to reach
US$ 144,734.5 Million by 2024 end. In 2016, the global market was valued at over US$ 49,994
Million characterizing the overwhelming popularity of antibody/antibody drugs amongst both
practitioners and patients observed in recent years.
Combination antibody therapy is receiving higher recognition from the oncological branch of
medical science research. This is primarily due to the growing use of combination therapy over
single drug treatments such as radiation or chemotherapy. In addition, companies that
manufacture combination antibody drugs are actively focusing on developing superior drugs that
will deliver standout results. Factors such as encouraging government policies, growing
concerns over higher cancer prevalence worldwide, and increasing research and development
activities coupled with heavier investments are expected to boost the overall market growth in
the near future. Likewise, healthy R&D pipelines are leading towards higher product offerings
and also propelling the growth of global combination antibody therapy market to a
significant extent.
A Sample of this Report is Available Upon Request @
http://www.persistencemarketresearch.com/samples/11740
Bottlenecks
The prolonged attrition rate in product development cycle and arbitrary and stringent drug
approval procedures are the major downsides of the market that are likely to inhibit the market
growth during the forecast period. Moreover, lack of awareness on understanding the difference
between immunotherapies and chemotherapies amongst healthcare professionals, which is
restricting the optimal use of immunotherapies alongside conventional treatment modalities is an
additional factor impeding the market growth. Further, late diagnosis or ignorance of any
carcinogenic disorders may inevitably lead to higher cost of treatment.
Market Forecast
Based on combinations, antibody/antibody is projected to be the predominant segment of the
market over the forecast period. In terms of revenue, the segment is expected to witness a
healthy CAGR of over 17% between 2016 and 2024. The growth is attributed to the increasing
preference of antibody/antibody drugs as they have a lower risk of side effects for various cancer
therapies. Whereas, the chemotherapy/antibody segment will hold the second position,
accounting for 38.3% share of the market in 2016.

3. Combination Antibody Therapy Market 2024
PersistenceMarketResearch
Demand for combination antibody therapy will be high for breast cancer and lung cancer
treatment on the basis of applications. The lung cancer segment is anticipated to expand at a
value CAGR of 17.1% during the assessment period.
By end user, hospitals are expected to be the largest segment of the market throughout the
forecast period. In 2015, the segment was valued at US$ 26,906.5 Million, which is expected to
surpass US$ 95,885 Million by 2024 end, reflecting a CAGR of 15.2%.
From a regional perspective, North America will continue to be the leading market for
combination antibody therapy over the forecast period. In addition, the region is set to witness a
CAGR of over 13% in terms of value. Whereas, APAC is expected to reflect the fastest growth of
the market during the forecast period in terms of value. Further, the market in the region is
estimated to witness a 3.4X growth in terms of sales over 2024 owing to increasing prevalence
of carcinogenic disorders in APAC.
Request to View Tables of Content @ http://www.persistencemarketresearch.com/market-
research/combination-antibody-therapy-market/toc
Key participants functioning in the global market for combination antibody therapy include Roche
Holdings AG, Amgen Incorporated, Novartis AG, Celgene Corporation, Biogen Inc., Seattle
Genetics Inc., Genmab A/S, Bristol-Myers Squibb Company, Eli-Lilliy and Company and Sanofi.
To Buy Full Report for a Single User @
http://www.persistencemarketresearch.com/checkout/11740
About Us:

4. Combination Antibody Therapy Market 2024
PersistenceMarketResearch
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a
unique collaboration of data analytics and market research methodology to help businesses
achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary
approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying
real-time data collection, big data, and customer experience analytics, we deliver business
intelligence for organizations of all sizes.
Our offerings include pre-built reports that address every major sale, customized solutions to
cater to client-specific needs, and consulting services to offer more value addition. Our next-
generation research approach for exploring emerging technologies has allowed us to solve the
most complex problems of clients. We do not follow a reactive approach, but a pro-active one.
Expert analysts at PMR keep a tab on next-generation technologies in their R&D phase and
provide the latest insights into these technologies when they are being commercialized. Our
ground-breaking approach allows us to deliver market solutions before the technologies reach
the market.
Our client success stories feature a range of clients from Fortune 500 companies to fast-growing
startups. PMR’s collaborative environment is committed to building industry-specific solutions by
transforming data from multiple streams into a strategic asset.
Contact Us:
Persistence Market Research
90 Sate Street, Suite 700 Albany, NY 12207
Tel: +1-518-618-1030
Email: sales@persistencemarketresearch.com
Website: http://www.persistencemarketresearch.com/
media@persistencemarketresearch.com
Stay updated with our official Blog: http://pmrblog.com